NDC product
Desvenlafaxine
NDC 0591-3660 · Actavis Pharma, Inc.
Key facts
| Product NDC | 0591-3660 |
|---|---|
| Proprietary name | Desvenlafaxine |
| Nonproprietary name | Desvenlafaxine |
| Substances | DESVENLAFAXINE SUCCINATE |
| Dosage form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Labeler | Actavis Pharma, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA204065 |
| Pharmacologic classes | Cytochrome P450 2D6 Inhibitors [MoA], Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC] |
| Marketing start | Mar 1, 2017 |
| Marketing end | Jan 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory